top of page
Chemical works

​R&D

CAR-T cell therapy technology development strategy

Development of CAR Pool platform for antibody genes by utilizing AI technology

Development of treatment for refractory diseases and product approval of 7 types (Blood cancer,
pancreatic cancer, Liver cancer, Lung cancer, Autoimmune disease, Dementia, combination therapy, etc.)

Priority development of CAR-T cells targeting blood cancer

  1. Hematological cancer treatment based on Next-generation CAR-T

  2. Rapid Clinical trial entry to validate the Safety & Efficacy of CAR-T treatment

  3. Optimization of dosage and route of administration of CAR-T cells

  4. Expand application to Solid cancer with the same CAR-T

Development of Next-generation CAR-T that overcomes Cancer Microenvironment and minimizes side effects

  1. Allogeneic CAR for immediate treatment in emergency situations

  2. Development of CAR that can be used for T cells and NK cells

Easily accessible CAR: 'Off-the-Shelf' Uni-CAR

  1. Introduce cytokines that can break the immunosuppressive environment and strongly induce immune activity (Cy-CAR)

  2. Minimize side effects by binding to cancer-targeting proteins and secreting cytokines around cancer cells

  3. Development of CAR-T (Home CAR) that can greatly move to cancer tissue 

Laboratory

​CarBio Therapeutics develops anti-cancer CAR-T immune cell therapy for patients suffering from serious diseases

Strategy

치료제 개발 디자인3_00000.png

CAR-T

Platform

(TKI, Tyrosine Kinase inhibitor)

CAR-T cell therapy technology development strategy

Development of CAR Pool platform for antibody genes by utilizing AI technology

Development of treatment for refractory diseases and product approval of 7 types (Blood cancer,
pancreatic cancer, Liver cancer, Lung cancer, Autoimmune disease, Dementia, combination therapy, etc.)

Priority development of CAR-T cells targeting blood cancer

  1. Hematological cancer treatment based on Next-generation CAR-T

  2. Rapid Clinical trial entry to validate the Safety & Efficacy of CAR-T treatment

  3. Optimization of dosage and route of administration of CAR-T cells

  4. Expand application to Solid cancer with the same CAR-T

Development of Next-generation CAR-T that overcomes Cancer Microenvironment and minimizes side effects

  1. Allogeneic CAR for immediate treatment in emergency situations

  2. Development of CAR that can be used for T cells and NK cells

Easily accessible CAR: 'Off-the-Shelf' Uni-CAR

  1. Introduce cytokines that can break the immunosuppressive environment and strongly induce immune activity (Cy-CAR)

  2. Minimize side effects by binding to cancer-targeting proteins and secreting cytokines around cancer cells

  3. Development of CAR-T (Home CAR) that can greatly move to cancer tissue 

전시회 부스.png
bottom of page